Literature DB >> 21920188

Current issues and available options in combined hormonal contraception.

Johannes Bitzer1, James A Simon.   

Abstract

Development of hormonal contraception marked a revolutionary step in social change that has improved the lives of women and families worldwide. Since the first oral contraceptive was introduced in the 1960s, hormonal contraception has undergone various stages of advancement. Today, oral contraceptive regimens are safer and more tolerable, with equal or improved efficacy, than the early formulations. Incremental decreases in the dose of estrogens have helped to alleviate some of the unwanted estrogenic side effects of combined hormonal contraceptives. Progestogens have also evolved over time, and newer generations of progestins have minimal side effects. New delivery methods have further extended the range of options available to women. Among these, the transdermal patch and vaginal ring are widely used. This review examines available combined hormonal contraceptive options and compares them, where data are available, for efficacy, safety, cycle control, adverse events profiles and associated risks, and user preference and satisfaction. We also examine particular areas of interest, including bone mineral density, venous thrombosis and use of antiepileptic drugs.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21920188     DOI: 10.1016/j.contraception.2011.02.013

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

1.  Types of combined oral contraceptives used by US women.

Authors:  Kelli Stidham Hall; James Trussell
Journal:  Contraception       Date:  2012-07-06       Impact factor: 3.375

2.  Nomegestrol acetate/estradiol: in oral contraception.

Authors:  Lily P H Yang; Greg L Plosker
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

3.  Systematic Review of Ovarian Activity and Potential for Embryo Formation and Loss during the Use of Hormonal Contraception.

Authors:  Donna Harrison; Cara Buskmiller; Monique Chireau; Lester A Ruppersberger; Patrick P Yeung
Journal:  Linacre Q       Date:  2019-01-03

4.  Prevalence and Self-Perceived Experiences With the Use of Hormonal Contraceptives Among Competitive Female Cross-Country Skiers and Biathletes in Norway: The FENDURA Project.

Authors:  Tina P Engseth; Erik P Andersson; Guro S Solli; Bente Morseth; Tor Oskar Thomassen; Dionne A Noordhof; Øyvind Sandbakk; Boye Welde
Journal:  Front Sports Act Living       Date:  2022-04-14

5.  Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study.

Authors:  Roberto De Icco; Laura Cucinella; Irene De Paoli; Silvia Martella; Grazia Sances; Vito Bitetto; Giorgio Sandrini; Giuseppe Nappi; Cristina Tassorelli; Rossella E Nappi
Journal:  J Headache Pain       Date:  2016-08-04       Impact factor: 7.277

6.  Design, Synthesis, and in Vitro and in Vivo Evaluation of Ouabain Analogues as Potent and Selective Na,K-ATPase α4 Isoform Inhibitors for Male Contraception.

Authors:  Shameem Sultana Syeda; Gladis Sánchez; Kwon Ho Hong; Jon E Hawkinson; Gunda I Georg; Gustavo Blanco
Journal:  J Med Chem       Date:  2018-01-19       Impact factor: 7.446

7.  Values and preferences for contraception: A global systematic review.

Authors:  Ping Teresa Yeh; Hunied Kautsar; Caitlin E Kennedy; Mary E Gaffield
Journal:  Contraception       Date:  2022-05-04       Impact factor: 3.051

8.  Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover study.

Authors:  Wolfgang Junge; Doris Heger-Mahn; Dietmar Trummer; Martin Merz
Journal:  Drugs R D       Date:  2013-09

9.  Evaluation of factors associated with noncompliance in users of combined hormonal contraceptive methods: a cross-sectional study: results from the MIA study.

Authors:  Txantón Martínez-Astorquiza-Ortiz de Zarate; Teresa Díaz-Martín; Txantón Martínez-Astorquiza-Corral
Journal:  BMC Womens Health       Date:  2013-10-20       Impact factor: 2.809

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.